Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -$178.1 million.

  • Cytokinetics' Income towards Parent Company fell 18.95% to -$178.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$602.1 million, marking a year-over-year decrease of 7.41%. This contributed to the annual value of -$573.9 million for FY2024, which is 9.43% down from last year.
  • According to the latest figures from Q3 2025, Cytokinetics' Income towards Parent Company is -$178.1 million, which was down 47.96% from -$120.4 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Income towards Parent Company peaked at -$13.7 million during Q2 2022, and registered a low of -$178.1 million during Q3 2025.
  • Moreover, its 3-year median value for Income towards Parent Company was -$134.6 million (2023), whereas its average is -$141.1 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first slumped by 6,173.01% in 2021, then spiked by 76.76% in 2022.
  • Quarterly analysis of 5 years shows Cytokinetics' Income towards Parent Company stood at -$25.9 million in 2021, then plummeted by 417.27% to -$134.1 million in 2022, then decreased by 0.37% to -$134.6 million in 2023, then decreased by 9.95% to -$148.0 million in 2024, then dropped by 18.95% to -$178.1 million in 2025.
  • Its Income towards Parent Company was -$178.1 million in Q3 2025, compared to -$120.4 million in Q2 2025 and -$155.6 million in Q1 2025.